PharmiWeb.com - Global Pharma News & Resources
18-Sep-2018

Chemotherapy-Induced Nausea & Vomiting (CINV) Treatment - Worldwide Markets to 2026: A $3.62 Billion Opportunity

Chemotherapy-Induced Nausea & Vomiting (CINV) Treatment - Worldwide Markets to 2026: A $3.62 Billion Opportunity

PR Newswire

DUBLIN, Sept. 18, 2018

DUBLIN, Sept. 18, 2018 /PRNewswire/ --

The "Global Chemotherapy Induced Nausea and Vomiting Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

The global chemotherapy induced nausea and vomiting market was valued at US$ 2,057.4 Mn in 2017, and is expected to reach US$ 3,626.1 Mn by 2026, expanding at a CAGR of 6.5% from 2018 to 2026.

As per the latest research citings of National Cancer Institute, in 2016 there were approximately 15.5 million cancer survivors due to early intervention of chemotherapy. Business analysts predict the rise in survivors to be 20.3 million by 2030.

The etiology of CINV is not very well understood, however the involvement of the chemo trigger zone and gastrointestinal mucosa have been reported in multiple studies. The challenges associated with the antiemetic prescribed for CINV are non-adherence and lack of effective guidelines for CINV treatment. Newer antiemetic drugs such as palonosetron and aprepitant have shown good pharmacokinetic properties in adult cancer patients, still more clinical trials are required for its safety in children.

Serotonin receptor antagonist represents a major share in the chemotherapy induced nausea and vomiting treatment market. Excellent pharmacodynamics properties of newer 5HT3 receptor antagonist and availability in oral, intravenous and transdermal patches makes it popular among the physicians treating CINV.

Dopamine antagonist have found prominence in treating acute nausea with minimal side effects. NK1 receptor antagonist will project healthy growth during the forecast period on account of its optimum pharmacokinetic properties, and is found effective in the treatment of refractory nausea in patients suffering with chemotherapy induced nausea and vomiting.

North America is the global leader in chemotherapy induced nausea and vomiting treatment market. Domicile of market leaders such as Sanofi-Aventis, Helsinn Healthcare etc., manufacturing CINV drugs and increasing demand for chemotherapy drive the CINV treatment market in North America.

Technological advancement in the diagnostic kits results in accurate diagnosis of cancer, thereby enrolling patients on chemotherapy treatment in Europe.

Asia Pacific will project excellent growth during the forecast period due to factors such as rising prevalence of cancer and developing healthcare infrastructure. It serves as a lucrative market for generic antiemetic drugs employed for the treatment of chemotherapy induced nausea and vomiting.

Key Market Movements

  • Rising demand for chemotherapy as treatment option in patients suffering with cancer
  • Excellent clinical outcomes of drug combination serotonin receptor antagonist/NK1 receptor antagonist in CINV treatment
  • Affordable reimbursement scenario for generic antiemetic drugs employed for CINV treatment

Key Topics Covered

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Chemotherapy Induced Nausea and Vomiting Treatment Market Portraiture
2.2. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Class, 2017 (US$ Mn)
2.3. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Chemotherapy Induced Nausea and Vomiting Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Key Players, 2017

Chapter 4. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class
4.1. Overview
4.2. Serotonin Receptor Antagonist
4.3. Neurokinin NK1 Receptor Antagonist
4.4. Dopamine Antagonist
4.5. Benzodiazepine
4.6. Others (Corticosteroids, Cannabinoids)

Chapter 5. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography
5.1. Overview
5.2. North America Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016-2026
5.3. Europe Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016-2026
5.4. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market Analysis, 2016-2026
5.5. Latin America Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016-2026
5.6. Middle East & Africa Chemotherapy Induced Nausea and Vomiting Treatment Market Analysis, 2016-2026

Chapter 6. Company Profiles
6.1. Baxter Pharmaceuticals
6.2. Eisai, Inc.
6.3. Helsinn Healthcare
6.4. GlaxoSmithkline, Plc
6.5. Merck & Co. Inc.
6.6. ProStrakan, Inc.
6.7. Pfizer, Inc.
6.8. Sanofi-Aventis
6.9. Solvay Pharmaceuticals, Inc.
6.10. Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/pfws85/chemotherapyinduc?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/chemotherapy-induced-nausea--vomiting-cinv-treatment---worldwide-markets-to-2026-a-3-62-billion-opportunity-300714529.html

SOURCE Research and Markets

Editor Details

Last Updated: 18-Sep-2018